TISIDB

Summary
Symbol	TP53INP1
Name	tumor protein p53 inducible nuclear protein 1
Aliases	DKFZp434M1317; FLJ22139; P53DINP1; TP53INP1A; TP53INP1B; Teap; TP53DINP1A; p53-dependent damage-inducible nu ......
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytosol. Nucleus. Nucleus, PML body. Cytoplasmic vesicle, autophagosome. Note=Shuttles between the nucleus and the cytoplasm, depending on cellular stress conditions, and re-localizes to autophagosomes on autophagy activation.
Domain	PF14839 DOR family
Function	Antiproliferative and proapoptotic protein involved in cell stress response which acts as a dual regulator of transcription and autophagy. Acts as a positive regulator of autophagy. In response to cellular stress or activation of autophagy, relocates to autophagosomes where it interacts with autophagosome-associated proteins GABARAP, GABARAPL1/L2, MAP1LC3A/B/C and regulates autophagy. Acts as an antioxidant and plays a major role in p53/TP53-driven oxidative stress response. Possesses both a p53/TP53-independent intracellular reactive oxygen species (ROS) regulatory function and a p53/TP53-dependent transcription regulatory function. Positively regulates p53/TP53 and p73/TP73 and stimulates their capacity to induce apoptosis and regulate cell cycle. In response to double-strand DNA breaks, promotes p53/TP53 phosphorylation on 'Ser-46' and subsequent apoptosis. Acts as a tumor suppressor by inducing cell death by an autophagy and caspase-dependent mechanism. Can reduce cell migration by regulating the expression of SPARC.

> Gene Ontology [ TOP ]
Biological Process	GO:0000045 autophagosome assembly GO:0006914 autophagy GO:0006979 response to oxidative stress GO:0007033 vacuole organization GO:0007050 cell cycle arrest GO:0009266 response to temperature stimulus GO:0009314 response to radiation GO:0009408 response to heat GO:0009411 response to UV GO:0009416 response to light stimulus GO:0009636 response to toxic substance GO:0010506 regulation of autophagy GO:0010508 positive regulation of autophagy GO:0016236 macroautophagy GO:0030336 negative regulation of cell migration GO:0033194 response to hydroperoxide GO:0034599 cellular response to oxidative stress GO:0034644 cellular response to UV GO:0040013 negative regulation of locomotion GO:0045471 response to ethanol GO:0045786 negative regulation of cell cycle GO:0048102 autophagic cell death GO:0051271 negative regulation of cellular component movement GO:0071214 cellular response to abiotic stimulus GO:0071361 cellular response to ethanol GO:0071447 cellular response to hydroperoxide GO:0071478 cellular response to radiation GO:0071482 cellular response to light stimulus GO:0072331 signal transduction by p53 class mediator GO:0072702 response to methyl methanesulfonate GO:0072703 cellular response to methyl methanesulfonate GO:0097305 response to alcohol GO:0097306 cellular response to alcohol GO:0098754 detoxification GO:0098869 cellular oxidant detoxification GO:1901796 regulation of signal transduction by p53 class mediator GO:1905037 autophagosome organization GO:1990748 cellular detoxification GO:2000146 negative regulation of cell motility GO:2001233 regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway
Molecular Function	GO:0016209 antioxidant activity
Cellular Component	GO:0005776 autophagosome GO:0016604 nuclear body GO:0016605 PML body

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-5633007: Regulation of TP53 Activity R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation R-HSA-5633008: TP53 Regulates Transcription of Cell Death Genes R-HSA-6803204: TP53 Regulates Transcription of Genes Involved in Cytochrome C Release R-HSA-3700989: Transcriptional Regulation by TP53

Summary
Symbol	TP53INP1
Name	tumor protein p53 inducible nuclear protein 1
Aliases	DKFZp434M1317; FLJ22139; P53DINP1; TP53INP1A; TP53INP1B; Teap; TP53DINP1A; p53-dependent damage-inducible nu ......
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TP53INP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between TP53INP1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29267866	Melanoma	Promote immunity (T cell function)	This enhancement is mediated by TP53INP1, whose overexpression increased the susceptibility of melanoma cell lines to T-cell cytotoxicity (2549 cell line: P = .009, unpaired t test), whereas its knockdown impeded T-cell killing of Top1 inhibitor-treated melanoma cells (2549 cell line: P < .001, unpaired t test).

Summary
Symbol	TP53INP1
Name	tumor protein p53 inducible nuclear protein 1
Aliases	DKFZp434M1317; FLJ22139; P53DINP1; TP53INP1A; TP53INP1B; Teap; TP53DINP1A; p53-dependent damage-inducible nu ......
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TP53INP1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TP53INP1
Name	tumor protein p53 inducible nuclear protein 1
Aliases	DKFZp434M1317; FLJ22139; P53DINP1; TP53INP1A; TP53INP1B; Teap; TP53DINP1A; p53-dependent damage-inducible nu ......
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TP53INP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.442	0.288
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.83	0.546
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.162	0.883
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.338	0.349
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.325	0.846
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.357	0.869
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.267	0.525
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.339	0.842
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.178	0.926
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.386	0.738
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.823	0.632
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.068	0.498

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TP53INP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	TP53INP1
Name	tumor protein p53 inducible nuclear protein 1
Aliases	DKFZp434M1317; FLJ22139; P53DINP1; TP53INP1A; TP53INP1B; Teap; TP53DINP1A; p53-dependent damage-inducible nu ......
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TP53INP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TP53INP1
Name	tumor protein p53 inducible nuclear protein 1
Aliases	DKFZp434M1317; FLJ22139; P53DINP1; TP53INP1A; TP53INP1B; Teap; TP53DINP1A; p53-dependent damage-inducible nu ......
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TP53INP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TP53INP1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TP53INP1
Name	tumor protein p53 inducible nuclear protein 1
Aliases	DKFZp434M1317; FLJ22139; P53DINP1; TP53INP1A; TP53INP1B; Teap; TP53DINP1A; p53-dependent damage-inducible nu ......
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TP53INP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TP53INP1
Name	tumor protein p53 inducible nuclear protein 1
Aliases	DKFZp434M1317; FLJ22139; P53DINP1; TP53INP1A; TP53INP1B; Teap; TP53DINP1A; p53-dependent damage-inducible nu ......
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TP53INP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TP53INP1
Name	tumor protein p53 inducible nuclear protein 1
Aliases	DKFZp434M1317; FLJ22139; P53DINP1; TP53INP1A; TP53INP1B; Teap; TP53DINP1A; p53-dependent damage-inducible nu ......
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TP53INP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TP53INP1
Name	tumor protein p53 inducible nuclear protein 1
Aliases	DKFZp434M1317; FLJ22139; P53DINP1; TP53INP1A; TP53INP1B; Teap; TP53DINP1A; p53-dependent damage-inducible nu ......
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TP53INP1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TP53INP1